Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04288427 · ClinicalTrials.gov registry record · NA
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
A NA study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT04288427: Recruiting NA study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, sponsored by Beth Israel Deaconess Medical Center.
NCT04288427 is a NA study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 120 participants, below the 548-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04288427, a NA study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.
Primary Outcome
Validated questions of the AUA Urinary Symptom Score will be used every 6 months to assess efficacy of Finasteride treatment in improving lower urinary tract symptoms in the patient population. Based on previous randomized trials, it will be determined whether the patient is responsive or resistant to the treatment dependent on changes in their AUA Urinary Symptom Score at the first 12 month mark. For patients who are resistant to Finasteride, other medical or surgical treatments will be offered
Conditions Studied
Interventions
- DRUG Finasteride
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
What NCT04288427 shows while recruiting
NCT04288427 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 548-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (78% lower).
The record links to 8 conditions, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Finasteride is the first listed.
NCT04288427 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04288427 about?
NCT04288427 is a clinical study titled "5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy". The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified p...
What is the current status of trial NCT04288427?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2020-09-25. Estimated completion is 2026-11-30.
What conditions does trial NCT04288427 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Prostate Disease, Prostate Hyperplasia, Urinary Obstruction.
What interventions are being tested in trial NCT04288427?
The interventions under investigation include: Finasteride (DRUG).
Who is sponsoring clinical trial NCT04288427?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04288427 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04288427's enrollment target sits among peer trials
120 18th of 29 higher than 11 of 29 other Benign Prostatic Hyperplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Benign Prostatic Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ambulatory Long Length URodynamics Evaluation
RECRUITING · NA
-
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
RECRUITING · NA
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
-
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
RECRUITING · NA
-
PRescription Exercise for Older Men With Urinary Disease
RECRUITING · NA
-
Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of Prostate
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI